ReviewImmunology2012
T regulatory cells in B-cell malignancy - tumour support or kiss of death?
Review in Immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- Integrating single-cell and bulk transcriptomes identifies B cell features associated with neoadjuvant chemoradiotherapy sensitivity in rectal cancer.Scientific reports · 2026Article
- PredictingEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Overexpression of Potential Markers of Regulatory and Exhausted CD8International journal of molecular sciences · 2023Article
- Systemic immunological profile of children with B-cell acute lymphoblastic leukemia: performance of cell populations and soluble mediators as serum biomarkers.Frontiers in oncology · 2023Article
- Review
- Aberrant peripheral blood CD4Cancer immunology, immunotherapy : CII · 2020Article
- Regulatory effect of Act1 on the BAFF pathway in B-cell malignancy.Oncology letters · 2019Article
- Mutational landscape of canine B-cell lymphoma profiled at single nucleotide resolution by RNA-seq.PloS one · 2019Article
- Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy.Haematologica · 2018Review
- T cell senescence and CAR-T cell exhaustion in hematological malignancies.Journal of hematology & oncology · 2018Review
- Targeting regulatory T cells for improving cancer therapy: Challenges and prospects.Cancer reports (Hoboken, N.J.) · 2018Review
- Peripheral blood T cell alterations in newly diagnosed diffuse large B cell lymphoma patients and their long-term dynamics upon rituximab-based chemoimmunotherapy.Cancer immunology, immunotherapy : CII · 2017Article
- Article
- The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespectiveof the disease status.Haematologica · 2014Article
- Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma.Immunologic research · 2014Review
- Article
- Regulatory T cells in chronic lymphocytic leukemia: implication for immunotherapeutic interventions.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is well established that T regulatory (Treg) cells counteract tumour immunity. However, conflicting results describing the role of Treg cells in haematological tumours warrant further investigations to clarify the interactions between Treg cells and the tumour. B-cell malignancy derives from different stages of B-cell development and differentiation in which T cells play a profound role. The transformed B cell may still be in need of T-cell help to thrive but simultaneously they may be recognized and destroyed by cytotoxic lymphocytes. Recent reports demonstrate that Treg cells can suppress and even kill B cells as part of their normal function to rescue the body from autoimmunity. An emerging body of evidence points out that Treg cells not only inhibit tumour-specific T cells but may also have a role in suppressing the progression of the B-cell tumour. In this review, we discuss the origin and function of Treg cells and their role in patients with B-cell tumours.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.